LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

LLY

1,069.44

+0.7%↑

JNJ

208.01

-0.26%↓

ABBV

226.07

+0.71%↑

UNH

333.57

+1.87%↑

AZN

91.61

+0.99%↑

Search

Smith & Nephew PLC ADR

Открыт

32.9 0.3

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

32.62

Макс.

32.97

Ключевые показатели

By Trading Economics

Доход

100M

296M

Продажи

4.7M

3B

P/E

Средняя по отрасли

28.777

76.798

Дивидендная доходность

2.36

Рентабельность продаж

9.895

Сотрудники

17,000

EBITDA

6.5M

723M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+9.86% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

2.36%

2.37%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

207M

14B

Предыдущая цена открытия

32.6

Предыдущая цена закрытия

32.9

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Smith & Nephew PLC ADR График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

18 дек. 2025 г., 23:54 UTC

Популярные акции

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 дек. 2025 г., 23:51 UTC

Отчет

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 дек. 2025 г., 23:39 UTC

Главные движущие силы рынка

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 дек. 2025 г., 22:57 UTC

Приобретения, слияния, поглощения

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 дек. 2025 г., 21:40 UTC

Отчет

Nike Sales Tick Up, But China Weakness Persists

18 дек. 2025 г., 23:45 UTC

Обсуждения рынка

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 дек. 2025 г., 23:37 UTC

Обсуждения рынка
Отчет

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 дек. 2025 г., 23:36 UTC

Обсуждения рынка

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 дек. 2025 г., 23:03 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 дек. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 дек. 2025 г., 23:00 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 дек. 2025 г., 22:59 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 дек. 2025 г., 22:58 UTC

Приобретения, слияния, поглощения

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 дек. 2025 г., 22:57 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 дек. 2025 г., 22:56 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 дек. 2025 г., 22:55 UTC

Отчет

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 дек. 2025 г., 21:59 UTC

Отчет

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 дек. 2025 г., 21:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

18 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

18 дек. 2025 г., 21:35 UTC

Отчет

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 дек. 2025 г., 21:31 UTC

Отчет

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Greater China Rev Down 17% >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q EPS 53c >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Apparel Rev $3.91B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Equipment Rev $550M >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q N Amer Rev $5.63B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Footwear Rev $7.66B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Greater China Rev $1.42B >NKE

Сравнение c конкурентами

Изменение цены

Smith & Nephew PLC ADR Прогноз

Целевая цена

By TipRanks

9.86% рост

Прогноз на 12 месяцев

Средняя 35.75 USD  9.86%

Максимум 37.5 USD

Минимум 34 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Smith & Nephew PLC ADR на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

2 ratings

0

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

26.64 / 28.37Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat